Artificial intelligence is rapidly transforming the life sciences sector — and its impact on the medical devices industry is particularly significant, especially after the coming into force of the EU AI Act. From diagnostics to patient monitoring and personalized treatments, AI-powered medical technologies are reshaping the future of healthcare in Italy, Europe, and globally. But as innovation accelerates, so does the need for a robust legal framework — especially under the recently adopted AI Act.
The final version of the Italian guidelines on certification for online gambling systems introduce a stricter and more comprehensive regulatory framework, setting new technical and procedural standards for platform compliance.
The potential classification of activities associated with ransomware cyberattacks, including ransom payments by victims, as a crime has long been an unresolved issue, also in Italy. This concern has now led Italy to introduce a groundbreaking legislative proposal aimed at enhancing cybersecurity and mitigating threats posed by digital extortionists.
In less than 50 days, relevant provisions of the EU AI Act will become applicable making even more paramount for businesses to ensure compliance in the exploitation of artificial intelligence systems.
The European Commission has launched a consultation on high-risk AI systems to support the adoption of the implementing act under Article 6(2) of the AI Act which is a crucial step for any sort of business.
The NIS 2 Directive has issued a significant warning to companies within the European Union: the personal liability of directors for lack of compliance is now a critical issue that cannot be ignored and the responsible directors must be notified by the end of May 2025.
Gambling operators and their suppliers must address the NIS 2 obligations, which impose stringent cybersecurity requirements across the European Union.
